CIK: 0001704132 · Show all filings
Period: Q4 2024 (← Previous) (Next →)
Filing Date: Feb 14, 2025
Total Value ($000): $108,797 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| PHVS | Pharvaris N.V. | 4,397,881 | $84,307 | 77.5% | $27.29 | -24.6% | COM | N69605108 |
| KURA | Kura Oncology, Inc. | 1,726,882 | $15,041 | 13.8% | $20.39 | -29.4% | COM | 50127T109 |
| — | Lyell Immunopharma, Inc. | 8,325,000 | $5,328 | 4.9% | $16.24 | — | COM | 55083R104 |
| RLAY | Relay Therapeutics Inc. | 1,000,000 | $4,120 | 3.8% | $7.47 | -27.2% | COM | 75943R102 |